Clinical Trial: NCT01684397
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Roswell Park Cancer Institute |
| Information Provided By: | Roswell Park Cancer Institute |
| Last Update Posted: | 2026-11-05 |
Study Overview
Brief Summary
This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as bevacizumab, can prevent tumor growth by blocking the ability of tumor cells to grow and spread. Giving pazopanib hydrochloride together with bevacizumab may kill more tumor cells.
Official Title
Conditions
Intervention / Treatment
- Biological: Bevacizumab
- Other: Laboratory Biomarker Analysis
- Drug: Pazopanib Hydrochloride
- Other: Pharmacological Study
Other Study ID Numbers
- I 191711
- NCI-2012-01247
- 13-069
- I 191711
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Roswell Park Cancer Institute |
| Information Provided By: | Roswell Park Cancer Institute |
| Last Update Posted: | 2026-11-05 |
Study Overview
Brief Summary
This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as bevacizumab, can prevent tumor growth by blocking the ability of tumor cells to grow and spread. Giving pazopanib hydrochloride together with bevacizumab may kill more tumor cells.
Official Title
Conditions
Intervention / Treatment
- Biological: Bevacizumab
- Other: Laboratory Biomarker Analysis
- Drug: Pazopanib Hydrochloride
- Other: Pharmacological Study
Other Study ID Numbers
- I 191711
- NCI-2012-01247
- 13-069
- I 191711